Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

Journal of Clinical Pharmacology
Nagy A FaridSteven A Wrighton

Abstract

Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine-5'-diphosphate (ADP)-mediated platelet aggregation in vivo. These compounds are converted to thiol-containing active metabolites through a corresponding thiolactone. The 3 compounds differ in their metabolic pathways to their active metabolites in humans. Whereas ticlopidine and clopidogrel are metabolized to their thiolactones in the liver by cytochromes P450, prasugrel proceeds to its thiolactone following hydrolysis by carboxylesterase 2 during absorption, and a portion of prasugrel's active metabolite is also formed by intestinal CYP3A. Both ticlopidine and clopidogrel are subject to major competing metabolic pathways to inactive metabolites. Thus, varying efficiencies in the formation of active metabolites affect observed effects on the onset of action and extent of inhibition of platelet aggregation (IPA). Knowledge of the CYP-dependent formation of ticlopidine and clopidogrel thiolactones helps explain some of the observed drug-drug interactions with these molecules and, more important, the role of CYP2C19 genetic polymorphism on the pharmacokinetics of and pharmacodynamic response to clopidogrel. The lack of drug interaction poten...Continue Reading

Associated Clinical Trials

References

May 15, 1992·Thrombosis Research·T L YueG Feuerstein
May 1, 1992·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·J B KnudsenJ P Dickinson
Mar 1, 1987·Clinical Pharmacology and Therapeutics·A ColliG Scaltrini
Aug 1, 1985·British Journal of Haematology·J A JakubowskiD Deykin
May 27, 1996·Archives of Internal Medicine·J P Rindone, G Bryan
Dec 9, 1997·Clinical Pharmacology and Therapeutics·S R DonahueJ W Ko
Sep 12, 1998·Annals of Internal Medicine·P J SharisJ Loscalzo
Nov 24, 1998·The Annals of Pharmacotherapy·A Martínez Pérez-BalsaJ F Martí Massó
Jan 19, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·P LagorceF Bressolle
Feb 25, 1999·Pharmacotherapy·T R Whetsel, D M Bell
Mar 19, 1999·Neuroscience Letters·C Lillesaar, C Hildebrand
May 8, 1999·British Journal of Clinical Pharmacology·T TateishiS Kobayashi
Dec 14, 1999·European Journal of Clinical Pharmacology·B MangoldM R Marino
Sep 19, 2002·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·K E L McColl, P Kennerley
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jean-Marie PereilloClaudine Picard
Dec 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomas A Clarke, Lucy A Waskell
Jul 30, 2003·Clinical Pharmacokinetics·Thomas Lenz, Amy Wilson
Oct 18, 2003·The Journal of Pharmacology and Experimental Therapeutics·Tanja RichterUlrich M Zanger
Jan 8, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Deepak K Dalvie, Thomas N O'Connell
May 19, 2004·British Journal of Pharmacology·Kenji YonedaSei Kobayashi
May 25, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Miia TurpeinenOlavi Pelkonen
Jun 18, 2005·Clinical Pharmacology and Therapeutics·Miia TurpeinenKari Laine
Aug 23, 2005·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hajime Takikawa
Jan 18, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jessica L Fayer RehmelBarbara J Ring
Feb 10, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mary F PaineDarryl C Zeldin
Apr 26, 2006·Rapid Communications in Mass Spectrometry : RCM·Ramakrishna V S NirogiRavikumar Boosi
Jun 7, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jung-Won SuhHyo-Soo Kim

❮ Previous
Next ❯

Citations

Mar 5, 2013·Current Atherosclerosis Reports·Nilusha Gukathasan, Roxana Mehran
Oct 12, 2012·International Journal of Hematology·Fatemeh Moheimani, Denise E Jackson
Mar 16, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Nuggehally R Srinivas
Apr 13, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vincent Lai Ming Yip, Munir Pirmohamed
Oct 25, 2011·European Heart Journal·Carlo PatronoFreek Verheugt
Dec 16, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jyothi C TalakadDeepak Dalvie
May 6, 2011·Thrombosis and Haemostasis·H FernandoJ A Shaw
Oct 30, 2010·Stroke; a Journal of Cerebral Circulation·Christopher D AndersonJonathan Rosand
Dec 2, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Tadasuke ChitoseUNKNOWN Kumamoto Intervention Conference Study (KICS) Investigators
Aug 9, 2011·Drug Metabolism and Drug Interactions·Sandra L Close
Dec 15, 2010·Clinical Pharmacokinetics·Thomas N KakudaRichard M W Hoetelmans
Feb 16, 2011·Biomarkers in Medicine·Joseph A Jakubowski
Jun 2, 2011·Future Cardiology·Antonio Tello-MontoliuDominick J Angiolillo
Apr 16, 2013·Journal of Thrombosis and Thrombolysis·Wei Eric WangChunyu Zeng
Mar 15, 2014·Pharmacogenomics·Alfi YasminaVera H M Deneer
Oct 16, 2013·Clinical Pharmacokinetics·Marta Karaźniewicz-ŁadaFranciszek Główka
Apr 26, 2014·Future Cardiology·Julie H Oestreich, Paul P Dobesh
Mar 5, 2014·British Journal of Anaesthesia·K A Tanaka, K Subramaniam
Jul 6, 2014·Medizinische Klinik, Intensivmedizin und Notfallmedizin·J M Siller-Matula, G Delle Karth
Dec 21, 2011·Journal of Thrombosis and Thrombolysis·Peter DammanStefan K James
May 8, 2013·Journal of Cardiothoracic and Vascular Anesthesia·Adriana Dana Oprea, Wanda M Popescu
Jul 12, 2014·European Journal of Clinical Pharmacology·Jean-Philippe ColletUNKNOWN DOSAPI investigators
Feb 1, 2014·Medicina clínica·Antonio Tello-MontoliuMariano Valdés
Mar 23, 2012·Postgraduate Medicine·John C Stephens, Arman T Askari
Jul 13, 2012·Expert Opinion on Pharmacotherapy·Young-Hoon JeongPaul A Gurbel
Sep 25, 2014·Drug Development and Industrial Pharmacy·Wei SunZeng-Shou Wang
May 23, 2012·Expert Opinion on Drug Discovery·Amit S Kalgutkar, Deepak K Dalvie
Aug 4, 2011·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Mar 8, 2012·Expert Opinion on Drug Metabolism & Toxicology·Freddi I ZunigaDiane D-S Tang-Liu
Apr 26, 2013·Expert Opinion on Drug Discovery·Jiaqi Shan, Hongbin Sun
Nov 12, 2013·Expert Opinion on Drug Metabolism & Toxicology·Stuart A ScottJean-Sébastien Hulot
Dec 15, 2010·Expert Opinion on Investigational Drugs·Salvatore D TomaselloDominick J Angiolillo
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Mariano A GiorgiGuillermo Di Girolamo
Jan 8, 2013·Expert Opinion on Drug Metabolism & Toxicology·Jawed FareedIndermohan Thethi
Sep 16, 2010·Expert Opinion on Drug Metabolism & Toxicology·S Casey Laizure, Robert B Parker
Dec 15, 2015·Drug and Chemical Toxicology·Yiran ZhaiXin He
Apr 4, 2015·International Journal of Cardiology·Payman Shahabi, Marie-Pierre Dubé

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Drug Metabolism and Disposition : the Biological Fate of Chemicals
Jessica L Fayer RehmelBarbara J Ring
The New England Journal of Medicine
Lars WallentinMona Thorsén
The New England Journal of Medicine
Tabassome SimonFrench Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators
© 2022 Meta ULC. All rights reserved